Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan-Dec;66(1):e15787.
doi: 10.1111/ped.15787.

Therapeutic insights: Use of ceftazidime-avibactam in pediatric patients

Özge Metin Akcan  1 , Mustafa Gençeli  1 , Talha Üstüntaş  2 , Abdullah Akkuş  2 , Sevgi Pekcan  3 , Metin Doğan  4
Affiliations

Therapeutic insights: Use of ceftazidime-avibactam in pediatric patients

Özge Metin Akcan et al. Pediatr Int. 2024 Jan-Dec.

Abstract

Background: The increasing worldwide prevalence of multidrug-resistant (MDR) bacteria underscores the pressing demand for innovative therapeutic solutions. Ceftazidime-avibactam (CAZ-AVI) represents a promising new drug combination that has received approval for specific infection types. However, there is limited information regarding its application in pediatric patients.

Methods: This study investigates the effectiveness and adverse reactions associated with CAZ-AVI treatment in pediatric patients with life-threatening infections caused by MDR pathogens. The study was conducted at a tertiary children's hospital between December, 2021 and July, 2023.

Results: A total of 21 patients with life-threatening infections caused by MDR pathogens were enrolled in the study. All patients had underlying medical conditions: 10 had cerebral palsy, four had congenital neurometabolic disease, two had Nieman-Pick disease, two had cystic fibrosis, two had primary immunodeficiency, and one had leukemia. Among these, 12 patients had tracheostomies. Eight patients received CAZ- AVI monotherapy, and 13 patients received combination therapy. Microbiological eradication was achieved in 18 patients (85.7%), and a clinical response was observed in 20 patients (95.2%). Two patients (9.5%) experienced relapse with the same bacteria. One patient developed anaphylaxis, and one patient had elevated creatine phosphokinase levels that normalized following discontinuation of treatment. One patient died during the study period due to gastrointestinal bleeding.

Conclusions: Ceftazidime-avibactam may be a promising new drug option for the treatment of life-threatening infections caused by MDR Gram-negative microorganisms in pediatric patients. However, further studies with larger case series are needed to further evaluate the efficacy and safety of CAZ-AVI in this population.

Keywords: ceftazidime‐avibactam; child; multidrug‐resistant.

PubMed Disclaimer

References

REFERENCES

    1. Sanz Herrero F. Ceftazidime‐avibactam. Ver Esp Quimioter. 2022;35:40–42.
    1. Zhen S, Wang H, Feng S. Update of clinical application in ceftazidime‐avibactam for multidrug‐resistant gram‐negative bacteria infections. Infection. 2022;50:1409–1423.
    1. US Food and Drug Administration. Ceftazidime‐avibactam prescribing information. 2015. [Cited March 14, 2019]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s00...
    1. Uğraklı S. Could ozone therapy be a novel strategy for combating with multi‐drug resistant bacteria? Selcuk Med J. 2022;38:194–202.
    1. Wang W, Wang R, Zhang Y, Zeng L, Kong H, Bai X, et al. Ceftazidime‐avibactam as salvage therapy in pediatric liver transplantation patients with infections caused by Carbapenem‐resistant Enterobacterales. Infect Drug Resist. 2022;15:3323–3332.

LinkOut - more resources